Investig Clin Urol.
2024 Jan;65(1):16-22. 10.4111/icu.20230314.
2023 Korean sexually transmitted infections treatment guidelines for Mycoplasma genitalium by KAUTII
- Affiliations
-
- 1Department of Urology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Department of Urology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 3Department of Urology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 4Department of Urology, Gwangju Veterans Hospital, Gwangju, Korea
- 5Department of Urology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
- 6Department of Urology, Daegu Catholic University Medical Center, Daegu, Korea
- 7Department of Urology, Chonnam National University Medical School, Hwasun, Korea
- 8Department of Urology, Yeungnam University College of Medicine, Daegu, Korea
- 9Department of Urology, Dankook University College of Medicine, Cheonan, Korea
- KMID: 2550114
- DOI: http://doi.org/10.4111/icu.20230314
Abstract
- The Korean Association of Urogenital Tract Infection and Inflammation and the Korea Disease Control and Prevention Agency updated the Korean sexually transmitted infections (STIs) guidelines to respond to the changing epidemiologic trends, evolving scientific evidence, and advances in laboratory diagnostics and research. The main recommendations in the Mycoplasma genitalium infection parts of the Korean STIs guidelines 2023 revision are as follows: 1) For initial treatment: azithromycin 500 mg orally in a single dose, then 250 mg once daily for 4 days. 2) In case of treatment failure or recurrence, a macrolide susceptibility/resistance test is required, when susceptibility/resistance test is not feasible, doxycycline or minocycline 100 mg orally twice daily for 7 days, followed by azithromycin 1 g orally on the first day, then azithromycin 500 mg orally once daily for 3 days and then a test-of-cure should be considered 3 weeks after completion of therapy. 3) In case of macrolide sensitivity, doxycycline or minocycline 100 mg orally twice daily for 7 days, followed by azithromycin 1 g orally initial dose, then azithromycin 500 mg orally once daily for 3 days. 4) In case of macrolide resistance, doxycycline or minocycline 100 mg orally twice daily for 7 days, followed by moxifloxacin 400 mg orally once daily for 7 days. In the Korean STIs guideline 2023, macrolide resistance-guided antimicrobial therapy was emphasized due to the increased prevalence of macrolide resistance worldwide. Therefore, in case of treatment failure or recurrence, a macrolide susceptibility/resistance test is required.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Detection Rate of Mycoplasma genitalium in Patients with Sexually Transmitted Urethritis
- Comparison of the Anyplex II STI-7 and Seeplex STD6 ACE Detection Kits for the Detection of Sexually Transmitted Infections
- Trend Analysis of Sexually Transmitted Infection Treatments in Korea
- The Prevalence and Clinical Significance of Urethritis and Cervicitis in Asymptomatic People by Use of Multiplex Polymerase Chain Reaction
- Effects of infections with five sexually transmitted pathogens on sperm quality
